WHO ICTRP trial
Combination therapy in rheumatoid arthritis
ISRCTN18445519 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN18445519 |
|---|---|
| Public title | Combination therapy in rheumatoid arthritis |
| Scientific title | Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a multicentre randomised open parallel-group treatment strategy trial |
| Primary sponsor | Turku University Hospital (Finland) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Finland |
| Conditions | Rheumatoid arthritis Musculoskeletal Diseases Other rheumatoid arthritis |
| Interventions | Combination therapy started with sulphasalazine 500 mg twice daily, methotrexate 7.5 mg weekly, and hydroxichloroquine 300 mg daily, and prednisolone 5 mg daily. This initial combination, if tolerated, was continued for 3 months. If the… |
| Registration date | Nov 27, 2009 |
| Target size | 199 |
| Secondary IDs | 31.1.1993 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: